United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

26 May 2017
Change (% chg)

$-0.02 (-3.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for RPRX.OQ


Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally... (more)


Beta: 0.58
Market Cap(Mil.): $15.34
Shares Outstanding(Mil.): 29.43
Dividend: --
Yield (%): --


  RPRX.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.73 -- --
ROI: -218.62 -8.48 -5.42
ROE: -231.25 -11.31 -4.68

BRIEF-Repros Therapeutics Q1 loss per share $0.22

* Repros Therapeutics Inc. reports first quarter 2017 financial results

May 09 2017

BRIEF-Repros Therapeutics meets with FDA to discuss Proellex in treatment of uterine fibroids

* Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids

Apr 10 2017

BRIEF-Repros names Larry Dillaha M.D. its permanent president and CEO

* Repros names Larry Dillaha, M.D., its permanent president and ceo

Apr 10 2017

BRIEF-Repros Therapeutics Inc reports • Q4 loss per share $0.16

* Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results

Mar 31 2017

BRIEF-Repros announces new CEO

* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage:

Feb 02 2017

More From Around the Web

Earnings vs. Estimates